At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies globally. He is currently a board member of Bioheng, Harton Therapeutics, Mammoth Biosciences, Mirvie, and Shape Therapeutics. He previously served on the boards ofAlpine Immune Sciences (acquired by Vertex), ARMO BioSciences (acquired by Eli Lilly), China Biologic Products, Cirina, Cue Health, GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), GRAIL (acquired by Illumina), ImmPACT Bio (acquired by Lyell), Ion Torrent Systems (acquired by Life Technologies), Sino Medical, and Velos Biopharma (acquired by Merck).
Prior to founding Decheng Capital in 2011, Dr. Cui spent five years at Bay City Capital, a leading international life science venture capital firm in San Francisco. He was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that were approved by the U.S. FDA. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in the discovery and development of several key technologies in the fields of oncology, cardiology, infectious diseases, and inflammatory diseases.
Dr. Cui received his B.S. and M.S. in Molecular Biology from Peking University, and his Ph.D. in Cancer Biology from Stanford University. Dr. Cui is currently on the board of trustee at Western University of Health Sciences.
What is Xiangmin Cui's net worth?
The estimated net worth of Xiangmin Cui is at least $18.11 million as of June 24th, 2024. Cui owns 2,175,236 shares of Nuvation Bio stock worth more than $18,108,840 as of December 5th. This net worth evaluation does not reflect any other investments that Cui may own. Learn More about Xiangmin Cui's net worth.
How do I contact Xiangmin Cui?
Has Xiangmin Cui been buying or selling shares of Nuvation Bio?
Xiangmin Cui has not been actively trading shares of Nuvation Bio during the last quarter. Most recently, on Monday, June 24th, Xiangmin Cui bought 336,874 shares of Nuvation Bio stock. The stock was acquired at an average cost of $2.98 per share, with a total value of $1,003,884.52. Following the completion of the transaction, the director now directly owns 2,175,236 shares of the company's stock, valued at $6,482,203.28. Learn More on Xiangmin Cui's trading history.
Who are Nuvation Bio's active insiders?
Are insiders buying or selling shares of Nuvation Bio?
During the last year, Nuvation Bio insiders bought shares 2 times. They purchased a total of 500,000 shares worth more than $818,000.00. During the last year, insiders at the sold shares 8 times. They sold a total of 340,000 shares worth more than $2,100,800.00. The most recent insider tranaction occured on December, 1st when insider Dongfang Liu sold 150,000 shares worth more than $1,173,000.00. Insiders at Nuvation Bio own 29.9% of the company.
Learn More about insider trades at Nuvation Bio. Information on this page was last updated on 12/1/2025.
